Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company specializing in the development of Tecarfarin, a novel therapy designed to prevent systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company's focus on addressing the unmet medical needs of this specific patient population positions them to generate revenue through the successful development and commercialization of Tecarfarin as an orphan drug therapy.

Products

• Tecarfarin